The BCG Vaccine is a vaccine containing bacillus Calmette-Guerin (BCG), an attenuated strain of Mycobacterium bovis, with non-specific immunoadjuvant and immunotherapeutic activities. Although the mechanism of its anti-tumor activity is unclear, immunization with BCG vaccine likely activates a Th1 cytokine response that includes the induction of interferon. Vaccination with BCG vaccine may be immunoprotective against infection with Mycobacterium tuberculosis.
It was recently announced that new estimates indicated over 650,000 children develop tuberculosis (TB) every year in the 22 countries with a high burden of the disease (HBCs). Which countries are these and why are so many children developing TB in these areas?
Leading immunologists expect to see some clear advances in the fight against tuberculosis, an infectious disease that is widespread the world over. Professor Stefan Kaufmann, Director at the Max Planck Institute for Infection Biology in Berlin, echoed these sentiments at today's launch of the scientific programme for the 64th Lindau Nobel Laureate Meeting at Lindau, Germany.
A new screening process for tuberculosis (TB) infections in Canadian prisons could mean that more than 50 per cent of those screened won't undergo unnecessary treatment due to false positives.
ILiAD Biotechnologies, LLC, the French National Institute of Health and Medical Research subsidiary, Inserm Transfert SA, and Institut Pasteur de Lille today announced the signing of scientific collaboration and worldwide license agreements for live attenuated Bordetella pertussis vaccine technology, including BPZE1, developed by the laboratory of Professor Camille Locht. This license agreement covers patent rights from Institut Pasteur de Lille, Inserm, National University of Singapore and National University of Ireland Maynooth.
The BCG vaccine has been found to be more effective against the most common form of tuberculosis than previously thought, according to a new study in Clinical Infectious Diseases.
New findings from two integrated Phase 3 Janssen Research & Development, LLC (Janssen)-sponsored studies showed treatment with STELARA- (ustekinumab) resulted in significantly greater inhibition of structural damage in patients with active psoriatic arthritis compared with placebo.
Any beneficial effects of the neonatal Bacillus Calmette–Guérin vaccine on childhood asthma symptoms and outcomes are likely to be transient, disappearing by adolescence, show follow-up findings from the Manchester Community Asthma Study.
A tuberculosis vaccine developed at McMaster University offers new hopes for the global fight against tuberculosis.
Janssen Biotech, Inc., announced today that the U.S. Food and Drug Administration (FDA) has approved STELARA® (ustekinumab) alone or in combination with methotrexate for the treatment of adult patients (18 years or older) with active psoriatic arthritis.
Imaxio, a biopharmaceutical company specializing in vaccines and genomics, announces today that IMX313, its proprietary pro-immunogenic technology, has been administered for the first time in humans in a tuberculosis vaccine phase I clinical study. The trial is being conducted by the Jenner Institute at Oxford University, England.
A team of Johns Hopkins researchers working with animals has developed a vaccine that prevents the virulent TB bacterium from invading the brain and causing the highly lethal condition TB meningitis, a disease that disproportionately occurs in TB-infected children and in adults with compromised immune system.
TB is an infectious disease caused by Mycobacterium tuberculosis. Nearly 9 million people develop TB every year, and TB kills nearly 1.4 million individuals each year. While the incidence of TB has steadily declined in the west, it remains a huge public health problem in many developing countries, with India having the highest burden.
The first of a series of new vaccines that have been developed to combat tuberculosis failed to show efficacy compared with placebo in South African infants, show results from a phase II trial.
"Hopes that a much needed new tuberculosis [TB] vaccine was on the way, the first for 90 years, have been dashed by trial results showing it did not protect babies against the disease," the Guardian reports.
"Today marks an important landmark for the fight against tuberculosis (TB)," with the publication in the Lancet of clinical trial results showing the TB vaccine candidate MVA85A "was no more effective in protecting infants from developing pulmonary TB than" the standard Bacillus Calmette-Guerin (BCG) vaccine, Peggy Johnston, senior program officer at the Bill & Melinda Gates Foundation, writes in the foundation's "Impatient Optimists" blog.
Governments meeting at the World Health Organization’s Executive Board (WHO EB) this week must seize the opportunity to improve serious shortcomings in the document that will drive the global community’s vaccines response in the next few years. If they fail to do so, key reasons why children continue to be missed by immunisation programmes will be left unaddressed.
"Researchers will find out early next year whether the first new vaccine against tuberculosis [TB] for 90 years protects against a disease that was once neglected but is now resurgent worldwide," Financial Times reports.
Patients with active psoriatic arthritis receiving the interleukin (IL)-12/23 inhibitor STELARA (ustekinumab) experienced significant improvements in signs and symptoms of the disease, according to new findings presented today from a Janssen Research & Development, LLC, (Janssen)-sponsored investigational study.
The National Institutes of Health (NIH) has awarded researchers at Albert Einstein College of Medicine at Yeshiva University a five-year, $5.9 million grant to develop a new vaccine against tuberculosis (TB), including the toughest-to-treat forms of the disease known as multi drug-resistant and extensively drug-resistant. The grant will build on a new approach to TB vaccine design that is based on genetically altered Mycobacterium smegmatis, which is closely related to the bacterial species (Mycobacterium tuberculosis) that causes TB in humans.
The tuberculosis vaccine is often used as a treatment for bladder cancer, and adding vitamin D might improve the vaccine's effectiveness, according to new research from the University of Rochester Medical Center presented today at the American Urological Association annual meeting.